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Background: The purpose of the present study was to evaluate the effect of carotenoid astaxanthin (ASTA) on
human neutrophils treated with high glucose and free fatty acids (FFA) on the phagocytic capacity and reac-
tive oxygen/nitrogen species production.
Methods: The following parameters were evaluated: phagocytic capacity of neutrophils by using zymosan
particles, intracellular and extracellular superoxide anion (lucigenin and DHE probes), hydrogen peroxide
(H2O2 — phenol red), nitric oxide (Griess reagent) production, and maximal activity of G6PDH.
Results: There was a decreased phagocytic capacity of human neutrophils treated with high glucose (30 mM)
or FFA (0.1 mM) and a partial restoring of the phagocytic capacity after ASTA-treatment was observed. ROS
and RNS production was increased in neutrophils due to both high glucose and FFA. This increase in ROS/
RNS production was also partially prevented by ASTA treatment. Both glucose and FFA increased the
G6PDH activity. We show that ASTA provides a modest improvement of cellular functions after cells have
been treated with high glucose and FFA.
Conclusions: In summary, this study showed that both high glucose and a mixture of FFA are potent inducers
of ROS/RNS production on neutrophils as observed by higher levels of superoxide anion, hydrogen peroxide
and NO• production. Also, these metabolites decrease the phagocytic capacity of neutrophils and increase the
G6PDH activity. Overall, ASTA-treatment was able to reduce partially ROS/RNS production by reducing the
availability of NADPH and recover phagocytic capacity of neutrophils.© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Diabetes is a special condition where both glucose and free fatty
acids (FFA) are increased in plasma. This fact occurs by a reduced in-
sulin action on target tissues or a failure of insulin secretion by pan-
creatic β-cells. Chronic exposure to high glucose and FFA can cause
damage in different cell types by a variety of mechanisms including
‘glucolipotoxicity’. Because an elevated level of glucose is one of the
metabolic hallmarks of diabetes, much attention has been given to
the sugar's oxidative chemistry. One widely studied mechanism in-
volves autoxidation of glucose itself, which generates reactive oxygen
species (ROS) such as hydroxyl radical and also cross-links proteins
[1,2]. Other potential mechanisms include glucose and FFA-
stimulated mitochondrial oxidative phosphorylation, production of
reactive intermediates by phagocytic white blood cells at sites of
inﬂammation (e.g. atherosclerotic tissue), and peroxidation of
polyunsaturated fatty acids, all of which have been implicated in the
generation of reactive intermediates in vitro [3]. In fact, it has been3342000, São Paulo, SP, Brazil.
r (R. Otton).
vier OA license.reported that glucose and FFA initiate the formation of ROS in mus-
cles, adipocytes, pancreatic β-cells and other cells [4–6].
Patients with diabetes are affected by frequent episodes of acido-
sis caused by increasing metabolism of fatty acids. This pathological
condition is correlated with the high incidence of vascular disease,
for which there a strong correlation with tissue damage mediated
by oxidative stress [7–9]. However, there is considerable controversy
regarding the nature, magnitude, and mechanisms of oxidative stress
in the diabetic state. Overproduction of ROS or a failure in intracellu-
lar defenses against ROS has been held as one major contributor to
long-term diabetic complications [6,10–14].
Peripheral blood cells such as phagocytes (macrophages and neu-
trophils) are well known to be activated in diabetes and thus produce
large amounts of ROS. The major pathway through which neutrophils
generate oxidants begins with their membrane-bound NADPH-
oxidase, which produces superoxide with subsequent hydrogen per-
oxide production [15,16]. The peroxide can then be used by another
phagocyte enzyme, myeloperoxidase. The connection between this
pathway and diabetes may be that, at least in the artery wall of dia-
betic animals, hyperglycemia can activate protein kinase C [17,18],
which leads to phagocyte activation, secretion of myeloperoxidase,
and oxidant generation. These changes might enhance the production
of superoxide and hydrogen peroxide, which myeloperoxidase
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acid. Superoxide anion can react with nitric oxide (NO∙) and produces
peroxinitrite, a powerful oxidant agent. Free fatty acids that common-
ly are overabundant in diabetes can also activate phagocytes in vitro
[19,20].
Uncontrolled ROS production can cause oxidative damage to a va-
riety of biologic macromolecules such as nucleic acids (DNA, RNA),
lipids, proteins and carbohydrates [21]. However, there are intracellu-
lar antioxidant defense mechanisms which involve both enzymatic
and non-enzymatic strategies. Among the non-enzymatic compounds
we can ﬁnd carotenoids that have antioxidant properties and a ther-
apeutic role in various diseases [22].
The ketocarotenoid astaxanthin (ASTA), 3,3′-dihydroxy-β,β-
carotene-4,4′-dione is ubiquitous in nature, especially in the
marine environment [23]. It is a red pigment common in many
marine animals, such as salmonids, shrimps, lobsters and crayﬁsh,
contributing to the pinkish-red color of their ﬂesh [24]. ASTA may
act as a strong antioxidant by donating the electrons and reacting
with free radicals to convert them into a more stable product and
terminate free radical chain reaction in a wide variety of living or-
ganisms [25,26]. In recent years, a major number of studies on ASTA
have demonstrated its antioxidant effect, for example the quenching
effect on singlet oxygen, a strong scavenging effect on superoxide,
hydrogen peroxide, and hydroxyl radicals and an inhibitory effect
on lipid peroxidation [27–30]. In addition, several other biologic ac-
tivities of ASTA, including anti-cancer, anti-inﬂammatory, antidia-
betic, immunomodulatory activities and a neuroprotective effect
also have been reported [25,31]. Antioxidants, including a number
of carotenoids, have been hypothesized to inhibit oxidative stress
and play a protective role against chronic diseases such as diabetes.
The purpose of this study was to evaluate the effects of ASTA in the
phagocytic capacity and ROS/RNS production induced by FFA and
high glucose in human neutrophils.
2. Materials and methods
2.1. Reagents
Astaxanthin (ASTA) and most of the other chemicals were pur-
chased from Sigma-Aldrich Chemical Company (St. Louis, MO, USA),
excepting the RPMI-1640 culture medium and lucigenin, which
came from Invitrogen (CA, USA). Common reagents for buffers (e.g.
PBS) and regular laboratory solutions were obtained from Labsynth
(Diadema, SP, Brazil).
2.2. Subjects
The Ethical Committee of the Cruzeiro do Sul Univerity approved
the experimental procedure of this study. Around 30 healthy adult
women and men (mean age 28.0±9.0) were included in the present
study. The subjects recruited did not present any systemic or topical
therapeutic regimen, a smoking history, alcohol habits, obesity or
any other systemic diseases at least for the last 2 months (based on
an anamnesis protocol).
2.3. Cell isolation and culture condition
Neutrophils were obtained through the collection of human pe-
ripheral blood by venipuncture procedure in vacuum/siliconized
tubes containing 0.1 mM EDTA. Peripheral blood neutrophils were
isolated under sterile conditions by using a density gradient present
in the reagent Histopaque 1077 (Sigma-Aldrich), according to the
manufacturer's instruction. Brieﬂy, blood (~20 mL) was diluted
(1:2) with phosphate-buffered saline PBS (133.8 mM NaCl, 2.7 mM
KCl, 0.9 mM KH2PO4, 6.4 mM Na2H2PO2, pH 7.4) and centrifuged for
30 min, 300 g at room temperature. The plasma and the intermediarylayer were removed and both neutrophils and erythrocytes were col-
lected from the sediment. Erythrocytes were lysed with a hemolysis
solution (150 mM NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.4)
and subsequently centrifuged for 10 min (600 g at 4 °C). This proce-
dure was repeated twice for total red blood cell lyses. Thereafter, neu-
trophils were washed with PBS followed by centrifugation for 10 min
(600 g at 4 °C). After centrifugation, the neutrophils were counted in
a Neubauer chamber using Trypan blue (1%). Neutrophils (1×106/
mL) were cultured in 1 mL of RPMI-1640 medium supplemented
with 10% fetal bovine serum, 20 mM Hepes, 2 mM glutamine, and an-
tibiotics (streptomycin 100 units/mL and penicillin 200 units/mL).
The cells were treated with 0.1 mM of a mixture of free fatty acid
prepared as described in our previous study [32,33] and with high
glucose (30 mM) added or not of 2 μM of ASTA solubilized in DMSO.
Then, after treatmentwe had the following experimental groups: con-
trol (without treatment), high glucose, high glucose+ASTA, FFA and
FFA+ASTA. The cells were cultured at 5% CO2 for up to 24 h at 37 °C.
After this period, the cells were collected, centrifuged and stored at
−80 °C to assay enzyme activity. For acute effects of FFA and high glu-
cose on cell ROS production, after isolation, neutrophils were resus-
pended in Tyrode's solution (137 mM NaCl, 2.68 mM KCl, 0.49 mM
MgCl2, 12 mM NaHCO3, 0.36 mM NaH2PO4, 5.6 mM D-glucose, and
5 mM acid HEPES, pH 7.4) and freshly used.
2.4. Phagocytic capacity
Neutrophils (1×106 cell/mL) were incubated for 30 min at 37 °C
in 1 mL RPMI 1640 medium with opsonized zymosan particles and
treated with or without 2 μM of ASTA, 0.1 mM of FFA and 30 mM of
glucose. The particles (5×106/mL) were opsonized by incubation in
the presence of control serum for 30 min at 37 °C. The cells were in-
cubated with particles and counted after cytocentrifugation. The
score of phagocytosis was expressed after the counting of one hun-
dred cells. The number of particles phagocyted was multiplied by
one, two and three, according to a criterion established to score [34].
2.5. Dihydroethidium assay
Dihydroethidium (DHE) is a ﬂuorescence probe used to measure
the intracellular superoxide anion production. Once inside the cell,
DHE is rapidly oxidized to ethidium (a red ﬂuorescent compound)
by superoxide and/or H2O2 (in the presence of peroxidase). Neutro-
phils (5×105/well) were incubated with 5 μM DHE for 15 min at
room temperature in the dark. At the beginning of the assay, the
cells were stimulated with phorbol myristate acetate (PMA — 20 ng/
well), a promoter of respiratory burst in phagocytes and treated
with or without 2 μM of ASTA, 0.1 mM of FFA and 30 mM of glucose
in Tyrode's buffer for 30 min. The ﬂuorescence was analyzed in a
microplate reader (Tecan, Salzburg, Austria) (396 nm wavelength ex-
citation and 590 nm wavelength emission). Results are expressed as
relative ﬂuorescence units (RFU).
2.6. Lucigenin assay
The lucigenin chemiluminescent probe was utilized to measure the
extracellular superoxide anion content mainly produced through
NADPH-oxidase activation. Lucigenin releases energy in the form of
light after excitation by superoxide anion. The chemiluminescence pro-
duced was monitored by a luminometer for 20 min (Tecan, Salzburg,
Austria). Lucigenin (5 μM) was added to cells (5×105/well) treated
with or without 2 μM of ASTA, 0.1 mM of FFA and 30 mM of glucose in
Tyrode's buffer. The experiments were carried out in the presence and
absence of PMA (20 ng/well). The results are expressed as chemilumi-
nescence relative units. The statistical analysis was performed by AUC
calculation (area under the curve).
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Hydrogen peroxide (H2O2) production was measured according to
Pick andMizel [35], based on horseradish peroxidases, which catalyze
the phenol red oxidation by H2O2. Neutrophils (5×105/well) were in-
cubated with or without 2 μM of ASTA, 0.1 mM of FFA and 30 mM of
glucose in Tyrode's buffer, mixed with 0.28 mM phenol red and
horseradish peroxidase (1000 units/mg) at 37 °C for 1 h. The produc-
tion of H2O2 was measured in the absence and presence of PMA
(20 ng/well). The reaction was terminated by alkalinization (addition
of 10 μL of NaOH 1 M solution) and absorbance at 620 nm was
measured to evaluate H2O2 concentration (compared to a standard
curve).2.8. Nitric oxide production
NO• production was performed according to Ding et al. [36] through
nitrite determination. Nitric oxide is rapidly converted into nitrite in
aqueous solutions and, therefore, the total nitrite can be used as an in-
dicator of nitric oxide concentration. The spectrophotometric analysis
of the total nitrite content was performed by using the Griess reagent
(1% sulfanilic acid, 0.1% N-1-naphthyl-ethylenediamine dihydrochlor-
ide) in supernatants. Neutrophils (5×105/well) were cultured with or
without 2 μM of ASTA, 0.1 mM of FFA and 30 mM of glucose and LPS-
stimulated (10 ng/well) for 4 h in RPMI-1640 medium supplemented
with 10% fetal bovine serum. Then, the same volume of Griess was
added to cells and the absorbance was measured in 550 nm. The nitrite
concentration was determined using sodium nitrite as a standard
(0–60 μM).150ity2.9. Assay the glucose-6-phosphate dehydrogenase (G6PDH) activity
Glucose-6-phosphate dehydrogenase (G6PDH), EC 1.1.l.49, is a
key regulatory enzyme of the oxidative segment of the pentose-
phosphate pathway and produces reducing equivalents in the form
of NADPH to meet some cellular needs for reductive biosynthesis
and as a contribution to the maintenance of the cellular redox
state [37]. The neutrophils (5×106/well) after a culture of 24 h
were disrupted in the pH 8.0 extraction buffer consisting of 50 mM
Tris–HCl and 1 mM EDTA. The activity was assayed as described in
[38] and 0.05% (v/v) Triton-X-100 was added to the assay system
to complete the extraction of the enzyme. The following 334 μL
assay medium at pH 7.6 composed of 8.6 mM Tris–HCl, 6.9 mM
MgCl2, 0.4 mM NADP, 1.2 mM glucose-6-phosphate. The spectro-
photometric measurements were made in a microplate reader
(Tecan, Salzburg, Austria). Enzyme activity is expressed as nmol/
min/mg of protein.50
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The measurement of the speciﬁc enzyme activity of G6PDH was
entirely related to protein concentrations, which were estimated
by the Bradford method [39] using bovine serum albumin as a
standard.control ASTA glucose glu+ASTA FFA FFA+ASTA
0Sc
or
Fig. 1. The phagocytic capacity was measured by incorporation of opsonized zymosan
particles in human neutrophils (1×106/mL) treated with or without 2 μM of ASTA,
30 mM glucose and 0.1 mM FFA. Results are expressed as mean±SEM of at least 4 de-
terminations. (a) Signiﬁcantly different compared with the control group (pb0.0001).
(b) Signiﬁcantly different compared with the respective group without ASTA
(pb0.0001). (c) Signiﬁcantly different compared with the glucose group (pb0.01).
(d) Signiﬁcantly different compared with the FFA group (pb0.001).2.11. Statistical analysis
All data points are the mean values with standard errors of at least
three independent experiments. The data were analyzed by one-way
ANOVA followed by the Tukey's post-test. The software employed for
statistical analysis was GraphPad Prism (version 4; GraphPad Soft-
ware, San Diego, CA, USA).3. Results
3.1. Phagocytic capacity
The phagocytic capacity was measured by the incorporation of
opsonized zymosan particles (Fig. 1). There was a signiﬁcant decrease
in the phagocytic capacity of neutrophils after the cells were treated
with FFA and glucose of 46% and 39% respectively, when compared
with the control group. ASTA treatment promoted a signiﬁcant in-
crease in phagocytosis of neutrophils, as compared with the FFA and
glucose group, by 51% and 45%, respectively. The addition of ASTA
on the FFA group improved the phagocytic capacity of neutrophils
by 47% when compared with the FFA group. The same effect was ob-
served in the glu+ASTA group, which presented an improvement of
22% as compared with the glucose group.3.2. Superoxide anion production
There was an increase in intracellular superoxide anion produc-
tion as assayed by DHE after the treatment of the cells with glucose
and FFA to levels of control-stimulated group, indicating that both
metabolites can induce neutrophil ROS production (Fig. 2A). When
compared with the basal control group, glucose and FFA promoted
an increase of 98% and 97%, respectively. In cells treated with ASTA,
a decrease in superoxide anion production of about 43% was observed
as compared with the control group. The addition of ASTA was not ef-
fective in reducing the superoxide anion production induced by FFA
and glucose. On the contrary, it promoted an increase of 51% in super-
oxide production when compared to the FFA group.
The extracellular superoxide anion production was measured by
using lucigenin probe (Fig. 2B). There was a direct induction of
NADPH-oxidase by FFA which promoted a signiﬁcant increase in
O2•− production in cells. The treatment of FFA with ASTA was unable
to reduce superoxide anion production.3.3. Hydrogen peroxide production
To promote hydrogen peroxide production, human control neutro-
philswere activatedwith PMA (20 ng/well). The cellswere then treated
with or without 2 μM of ASTA and 30 mM of glucose or 0.1 mM of FFA
for 1 h. Hydrogen peroxide production was increased by 70%, 60%,
100% and 65% in ASTA, glucose, FFA, and FFA+ASTA respectively
when compared with the control-unstimulated group. A decrease of
34% in hydrogen peroxide production was observed in the glu+ASTA
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Fig. 2. (A) Intracellular (DHE) and (B) extracellular (lucigenin) superoxide anion pro-
duction in human neutrophils. Cells (5×105/well) were treated with or without 2 μM
of ASTA and activated with PMA (20 ng/well) or 30 mM glucose or 0.1 mM FFA for
30 min. Results are expressed as mean±SEM of at least 5 determinations. (a) Signiﬁ-
cantly different compared with the cont+PMA group (pb0.001). (b) Signiﬁcantly dif-
ferent compared with the ASTA group (pb0.001).
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compared to the FFA group (Fig. 3).3.4. Glucose-6-phosphate dehydrogenase activity
The maximum G6PDH activity was assessed by the reduction of
the co-factor NADP+ to NADPH in human neutrophils. G6PDH activ-
ity was increased 97% and 107% in glucose and FFA groups respective-
ly when compared to the control group. The addition of ASTA in
glucose and FFA groups promoted a decrease of 39% and 32% as com-
pared with glucose and FFA respectively (Fig. 4).control cont+PMA ASTA glucose glu+ASTA FFA FFA+ASTA
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Fig. 3. Hydrogen peroxide production evaluated by phenol red oxidation. Human neu-
trophils (5×105/well) were treated with or without 2 μM of ASTA and activated with
PMA (20 ng/well) or 30 mM glucose or 0.1 mM FFA for 60 min. Results are expressed
as mean±SEM of at least 5 determinations. (a) Signiﬁcantly different compared with
the unstimulated-control group (pb0.001). (b) Signiﬁcantly different compared with
the glucose group (pb0.001). (c) Signiﬁcantly different compared with the FFA group
(pb0.001).3.5. Nitric oxide production
The NO• production was evaluated in cells treated with glucose
(Fig. 5A) and FFA (Fig. 5B) in both basal and LPS-stimulated conditions.
An increase of 77%, 190% and 146% was observed in NO• production in
ASTA, glucose, and glu+ASTA groups respectively when compared
with the control-unstimulated group. After LPS-stimulation, the glucose
and glu+ASTA groups were increased by 74% and 50% respectively as
compared with the control-stimulated group. The treatment of cells
with FFA did not promote an increase in NO• production as observed
after the treatment of cells with high glucose. However, ASTA promoted
an increase of ~30% at both basal and LPS-stimulation conditions as
compared with the respective control group.4. Discussion
In the present study we observed a decreased phagocytic capacity
of human neutrophils (Fig. 1) when they were treated with high glu-
cose (30 mM) or FFA (0.1 mM) mimicking a diabetic condition in
vitro. A partial restoring of the phagocytic capacity was observed
after ASTA-treatment. Overall, ROS and RNS production was in-
creased in neutrophils due to both high glucose and FFA. This increase
in ROS/RNS production was also partially prevented by ASTA treat-
ment. Both glucose and FFA increased the G6PDH activity (Fig. 4),
probably by increasing the ﬂux of these metabolites throughout oxi-
dative pathways which result in increased NADPH co-factor content.
While ASTA has a potent antioxidant effect as shown by other au-
thors, in this study we show that ASTA has a modest improvement
of cellular functions after cells has been treated with high glucose
and FFA. This effect could be in part due to high stress imposed to
cells by the presence of high glucose and FFA. ASTA was unable to to-
tally abrogate the huge oxidative stress induced by these metabolites.
Proposed mechanisms for the pathogenesis of diabetic complica-
tions include the formation of advanced glycosylation end products
(AGEs), oxidative stress, carbonyl stress, increased protein kinase C
activity, altered growth factor or cytokine activities, and mitochondri-
al dysfunction [3,40,41]. Two factors that strongly affect the risk of di-
abetic complications are disease duration and degree of glycemic
control. These observations have given rise to the “glucose hypothe-
sis” which suggests that glucose mediates many of the deleterious ef-
fects of diabetes [3]. However, strict glycemic control alone does not
prevent diabetic complications, suggesting the involvement of addi-
tional factors. High levels of plasma FFA are also implicated in diabetic
complications [6,42].
A variety of types of recurrent infections draws attention to dia-
betic patients, not because of its ease of acquired infections, but alsocontrol ASTA glucose glu+ASTA FFA FFA+ASTA
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Fig. 4. Maximum G6PDH activity assessed by the reduction of the cofactor NADP+ to
NADPH in human neutrophils (1×106/mL) cultured for 24 h and treated with or without
2 μMof ASTA, 30 mMglucose and 0.1 mM FFA. Results are expressed asmean±SEM of at
least 5 determinations. (a) Signiﬁcantly different compared with the control group
(pb0.001). (b) Signiﬁcantly different compared with the respective group without ASTA
(pb0.001). (c) Signiﬁcantly different compared with the glucose group (pb0.001). (d)
Signiﬁcantly different compared with the FA group (pb0.001).
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Fig. 5. Nitric oxide production evaluated by Griess reagent. Human neutrophils
(5×105/well) were treated with or without 2 μM of ASTA and stimulated with LPS
(10 ng/well) or 30 mM glucose (A) or 0.1 mM FA (B) for 4 h. Results are expressed as
mean±SEM of at least 5 determinations. (a) Signiﬁcantly different compared with re-
spective control group (pb0.001). (b) Signiﬁcantly different compared with the ASTA
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Even simple and relatively benign pathogens can cause severe infec-
tions in these patients [43]. Hyperglycemia and high levels of FFA
were shown to decrease bactericidal activity, impair phagocytosis
and decrease the release of lysosomal enzymes, and reduce produc-
tion of reactive oxygen species by neutrophils of diabetic patients
[44–46]. In the present study glucose and a mixture of fatty acids
used at 0.1 mM caused a marked decrease in phagocytic capacity of
human neutrophils similar to the one observed in the diabetic condi-
tion. ASTA addition signiﬁcantly improves phagocytic capacity of neu-
trophils treated with glucose and FFA. A similar result was obtained
by our group previously [30].
Long-chain FFA and some of their derivatives and metabolites can
modify intracellular production of reactive oxygen species (ROS), in
particular superoxide and H2O2. In mitochondria, FFA exerts a dual ef-
fect on ROS production. Because of slowing down the rate of electron
ﬂow through Complexes I and III of the respiratory chain due to an in-
teraction within the complex subunit structure, and between Com-
plexes III and IV due to the release of cytochrome c from the inner
membrane, FFA increases the rate of ROS generation in the forward
mode of electron transport [47]. FFA can also modulate mitochondrial
ROS production by other mechanisms: (a) being protonophores, they
abolish RET (reverse electron transport) dependent on the superoxide
generation; (b) having a potential ability to interfere with various en-
zymatic processes, FFA could inactivate the regeneration of reduced
glutathione (GSH) from its oxidized form (GSSG), thus impeding re-
moval of H2O2 by glutathione peroxidase; (c) the amphiphilic nature
of FFA favors their incorporation into the inner mitochondrial mem-
brane with a consequent change of membrane ﬂuidity [47]. FFA are
also long known as an activators of the NADPH oxidase-dependent su-
peroxide production of neutrophils [48–51]. This non-mitochondrial
oxygen uptake is accompanied by the generation of superoxide and
H2O2 [52]. In our study there was a huge increase in superoxide
anion production in cells treated acutely with high glucose and FFA
as assayed by DHE and lucigenin probes (Fig. 2). The addition of
ASTA on the FFA group promoted a higher increase in superoxide pro-
duction. Vascular cells increase their ROS generation through the acti-
vation of NADPH oxidase induced by high glucose levels and FFA [53].
The neutrophil respiratory burst seems to be related directly to glyce-
mic control with an increase in protein kinase C (PKC) and NADPH ox-
idase activity [54–56]. Mechanistically, hyperglycemia results in
increased phosphorylation of p47phox, leading to an increase in the gen-
eration of superoxide anion [54–56]. Recent works have shown that
p47phox, a key protein in the assembly of NAPDH oxidase, prematurely
translocates to the membrane and associates with p22phox in neutro-
phils from diabetic subjects [57]. In the present study the mechanism
by which FFA and high glucose induce ROS production needs to be
clariﬁed.
Neutrophils are dependent on the production of reactive oxygen
species to exert their role in destroying pathogens during phagocytosis.
But these reactive oxygen species being produced in large amounts can
damage the cell, mainly because their membranes have a large amount
of polyunsaturated fatty acids, which are easily oxidized by these reac-
tive species.
Superoxide is rapidly converted into hydrogen peroxide (H2O2),
either spontaneously or enzymatically by superoxide dismutase. H2O2
is then reduced to water by catalase or converted into hypochlorous
acid (HOCl) by myeloperoxidase [58]. H2O2 can also be transformed
into hydroxyl radicals in the presence of transition metal ions [59]. In
this study we observed that the hydrogen peroxide production in neu-
trophils was increased (Fig. 3) when cells were treated with glucose
and FFA. Many authors have reported that astaxanthin has a greater af-
ﬁnity with hydrogen peroxide when compared to superoxide [27–29].
Recently, Macedo et al. [30] showed that astaxanthin signiﬁcantly re-
duced the production of pro-inﬂammatory cytokines, such as tumor
necrosis factor-α and interleukin-6 in lipopolysaccharide-stimulatedneutrophils. The authors also showed that astaxanthin improved neu-
trophil phagocytic and microbicidal capacity and reduced superoxide
anion and hydrogen peroxide production, which appeared to be medi-
ated by calcium released from intracellular storages and nitric oxide
production.
The interaction of glucose with proteins leading to the formation
of Amadori products and then AGEs is an important source of free
radicals in diabetes [40]. These AGEs, via their receptors (RAGE), inac-
tivate enzymes and alter their structures and functions [60], promote
free radical formation [41,61], and quench and block antiproliferative
effects of nitric oxide [62,63]. By increasing intracellular oxidative
stress, AGE activate the transcription factor NFκB (nuclear factor
kappa B), thus promoting up-regulation of various NFκB controlled
target genes [64,65]. NFκB enhances production of NO•, which is be-
lieved to be a mediator of islet beta cell damage [66]. We observed
an increase of 190% in NO· production (Fig. 5A) in cells treated with
high glucose. FFA was not a potent inducer of NO• production
(Fig. 5B). Whether the NFκB pathway is activated in these cells re-
mains to be elucidated. ASTA, as previously shown by our group
[29,30,33], increased NO• production both in lymphocytes and neu-
trophils, which was associated with a beneﬁcial anti-inﬂammatory
role of ASTA. In the present study ASTA also promoted a signiﬁcant
increase in NO•. Hussein and coworkers [25] also found an increase
in NO• production associated with a reduction of the arterial blood
pressure in spontaneously hypertensive rats, suggesting an anti-
hypertensive role of ASTA. Recently, Kim and colleagues [67] found
that ASTA reduced the activation of the transcription factor NF-κB
and decreased the IL-6 production in microglial cells. Since NFκB is
the most important pathway in immune cells, responsible of inducing
NO• production by inducing iNOS expression, we can speculate that
ASTA can promote a NF-κB activation which leads to an increase in
NO• production.
Defense mechanisms against free radical-induced oxidative stress
involve: (i) preventive mechanisms, (ii) repair mechanisms, (iii) phys-
ical defenses, and (iv) antioxidant defenses. Enzymatic antioxidant
2225B.A. Guerra, R. Otton / International Immunopharmacology 11 (2011) 2220–2226defenses include superoxide dismutase (SOD), glutathione peroxidase
(GPx), catalase (CAT). Non-enzymatic antioxidants are represented
by ascorbic acid (Vitamin C), α-tocopherol (Vitamin E), glutathione
(GSH), carotenoids, ﬂavonoids, and other antioxidants. Under normal
conditions, there is a balance between both the activities and the intra-
cellular levels of these antioxidants. This balance is essential for the sur-
vival of organisms and their health [68]. Some antioxidant enzyme
systems need the cofactor NADPH, which is produced mainly by the
pentose pathways through the enzyme glucose-6-phosphate dehydro-
genase (G6PDH). This cofactor is extremely important for several cellu-
lar processes.
In this study we evaluated the maximum activity of G6PDH and
our ﬁndings show that there was an increase in G6PDH activity in
cells treated with glucose and FFA. Probably, the high ﬂux of these
metabolites throughout the metabolic pathways was responsible for
increased G6PDH activity. In the pentose pathway, higher G6PDH ac-
tivity can raise the level of NADPH, which is an important co-factor
for antioxidants enzymes such as glutathione peroxidase and gluta-
thione reductase. In addition, NADPH is an essential co-factor for
NADPH-oxidase, an important pathway for ROS/RNS production.
Treatment with ASTA was able to restore G6PDH activity to control
levels, reducing the availability of NADPH for participation in ROS
production. Perhaps, the antioxidant role of ASTA observed in this
study is due to this speciﬁc action on pentose pathway.
In summary, this study showed that both high glucose and amixture
of FFA are potent inducers of ROS/RNS production on neutrophils as ob-
served by higher levels of superoxide anion, hydrogen peroxide and
NO• production. Also, thesemetabolites decrease the phagocytic capac-
ity of neutrophils and increase G6PDH activity. Overall, ASTA-treatment
was able to reduce partially the ROS/RNS production by reducing the
availability of NADPH and to recover phagocytic capacity of neutrophils.
However, it is important that further human studies be conducted to
evaluate the effect of astaxanthin in relation to its bioavailability, bio-
conversion and bioefﬁcacy to complement the ﬁndings in this study.
Soon the use of antioxidants such as astaxanthin may be indicated as
an adjunctive treatment to diabetes mellitus.
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